Ítem
Acceso Abierto

Incident cervical HPV infections in young women: Transition probabilities for CIN and infection clearance

dc.creatorInsinga R.P.spa
dc.creatorPerez, Gonzalospa
dc.creatorWheeler C.M.spa
dc.creatorKoutsky L.A.spa
dc.creatorGarland S.M.spa
dc.creatorLeodolter S.spa
dc.creatorJoura E.A.spa
dc.creatorFerris D.G.spa
dc.creatorSteben M.spa
dc.creatorHernandez-Avila M.spa
dc.creatorBrown D.R.spa
dc.creatorElbasha E.spa
dc.creatorMuñoz N.spa
dc.creatorPaavonen J.spa
dc.creatorHaupt R.M.spa
dc.date.accessioned2020-05-26T00:03:49Z
dc.date.available2020-05-26T00:03:49Z
dc.date.created2011spa
dc.description.abstractBackground: We describe transition probabilities for incident human papillomavirus (HPV) 16/18/31/33/35/45/52/58/59 infections and cervical intraepithelial neoplasia (CIN) 1 lesions. Methods: Women ages 16 to 23 years underwent cytology and cervical swab PCR testing for HPV at approximately 6-month intervals for up to 4 years in the placebo arm of an HPV vaccine trial. The cumulative proportion of incident HPV infections with diagnosed CIN, clearing (infection undetectable), or persisting without CIN, were estimated. Results: Most incident infections cleared, without detection of CIN, ranging at 36 months from 66.9% for HPV31 to 91.1% for HPV59. There was little variation in the 36-month proportion of incident HPV16, 18, and 31 infections followed by a CIN1 lesion positive for the relevant HPV type (range 16.7%-18.6%), with lower risks for HPV59 (6.4%) and HPV33 (2.9%). Thirty-six-month transition probabilities for CIN2 ranged across types from 2.2% to 9.1%; however, the number of events was generally too small for statistically significant differences to be seen across types for this endpoint, or CIN3. Conclusions: Some incident HPV types appear more likely to result in diagnosed CIN1 than others. The relative predominance of HPV16, vis-à-vis some other high-risk HPV types (e.g., HPV33) in prevalent CIN2/3, appears more directly associated with relatively greater frequency of incident HPV16 infections within the population, than a higher risk of infection progression to CIN2/3. Impact: Nearly all incident HPV infections either manifest as detectable CIN or become undetectable within 36 months. Some HPV types (e.g., 16 and 33) appear to have similar risk of CIN2/3 despite widely varied incidence. ©2011 AACR.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1158/1055-9965.EPI-10-0791
dc.identifier.issn10559965
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/23632
dc.language.isoengspa
dc.relation.citationEndPage296
dc.relation.citationIssueNo. 2
dc.relation.citationStartPage287
dc.relation.citationTitleCancer Epidemiology Biomarkers and Prevention
dc.relation.citationVolumeVol. 20
dc.relation.ispartofCancer Epidemiology Biomarkers and Prevention, ISSN:10559965, Vol.20, No.2 (2011); pp. 287-296spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-79951656791&doi=10.1158%2f1055-9965.EPI-10-0791&partnerID=40&md5=9cbafdec0919c1bce68dc4a6e7f6b947spa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordPlacebospa
dc.subject.keywordWart virus vaccinespa
dc.subject.keywordAdolescentspa
dc.subject.keywordAdultspa
dc.subject.keywordArticlespa
dc.subject.keywordCancer diagnosisspa
dc.subject.keywordCancer incidencespa
dc.subject.keywordControlled clinical trialspa
dc.subject.keywordControlled studyspa
dc.subject.keywordCytologyspa
dc.subject.keywordFemalespa
dc.subject.keywordHumanspa
dc.subject.keywordHuman papillomavirus type 16spa
dc.subject.keywordHuman papillomavirus type 18spa
dc.subject.keywordHuman papillomavirus type 31spa
dc.subject.keywordHuman papillomavirus type 33spa
dc.subject.keywordHuman papillomavirus type 35spa
dc.subject.keywordHuman papillomavirus type 45spa
dc.subject.keywordHuman papillomavirus type 52spa
dc.subject.keywordHuman papillomavirus type 58spa
dc.subject.keywordHuman papillomavirus type 59spa
dc.subject.keywordInfection riskspa
dc.subject.keywordNonhumanspa
dc.subject.keywordPapillomavirus infectionspa
dc.subject.keywordPathogen clearancespa
dc.subject.keywordPolymerase chain reactionspa
dc.subject.keywordPriority journalspa
dc.subject.keywordRandomized controlled trialspa
dc.subject.keywordUterine cervix carcinoma in situspa
dc.subject.keywordAdolescentspa
dc.subject.keywordAdultspa
dc.subject.keywordCervical intraepithelial neoplasiaspa
dc.subject.keywordCervix uterispa
dc.subject.keywordDouble-blind methodspa
dc.subject.keywordFemalespa
dc.subject.keywordFollow-up studiesspa
dc.subject.keywordHumansspa
dc.subject.keywordIncidencespa
dc.subject.keywordInternational agenciesspa
dc.subject.keywordPapillomaviridaespa
dc.subject.keywordPapillomavirus infectionsspa
dc.subject.keywordPapillomavirus vaccinesspa
dc.subject.keywordPlacebosspa
dc.subject.keywordPrevalencespa
dc.subject.keywordPrognosisspa
dc.subject.keywordRisk factorsspa
dc.subject.keywordSurvival ratespa
dc.subject.keywordUterine cervical neoplasmsspa
dc.subject.keywordYoung adultspa
dc.titleIncident cervical HPV infections in young women: Transition probabilities for CIN and infection clearancespa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Bloque original
Mostrando1 - 1 de 1
Cargando...
Miniatura
Nombre:
287-full.pdf
Tamaño:
210.54 KB
Formato:
Adobe Portable Document Format
Descripción:
Colecciones